Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13%

Supernus Pharmaceuticals Inc (SUPN) reported mixed results for its fiscal 2025 Q2 earnings on August 5, 2025. While the company saw a modest revenue decline, net income increased by 13% year-over-year. Supernus also raised full-year revenue guidance, citing strong first-half performance and the impact of its recent Sage Therapeutics acquisition.

Revenue
Supernus’s total revenue for the second quarter of 2025 was $165.45 million, representing a 1.7% decrease compared to $168.32 million in the same period in 2024. Within the revenue mix, net product sales contributed $158 million, forming the largest portion of the company’s top-line results. Royalty, licensing, and other revenues accounted for the remainder, totaling $7.46 million. The slight decline in total revenue reflects ongoing market dynamics and competitive pressures, though the company continued to see strong performance from key therapeutic areas.

Earnings/Net Income
Supernus posted a 13.0% increase in net income, reaching $22.50 million in Q2 2025 compared to $19.92 million in Q2 2024. Earnings per share (EPS) also improved, rising to $0.40 from $0.36, a 11.1% year-over-year increase. The positive EPS trend reflects improved profitability and cost management, despite the modest revenue contraction.

Price Action
Following the earnings announcement, Supernus shares have shown strong momentum, gaining 1.90% on the latest trading day, 12.20% for the week, and 17.35% month-to-date.

Post Earnings Price Action Review
The strategy of buying Supernus shares following earnings reports and holding for 30 days has delivered consistent returns over the past three years. The approach has generated a 20.56% gain, outperforming broader market benchmarks. The positive returns are attributed to Supernus’s ability to consistently exceed revenue expectations and raise guidance. The company's strong product performance, particularly with Qelbree and ONAPGO, has reinforced investor confidence. A 30-day holding period effectively balances the potential for post-earnings volatility with the likelihood of sustained positive momentum from favorable market sentiment.

CEO Commentary
Jack Khattar, President and CEO of Supernus, highlighted the company’s robust first-half performance, driven by 31% and 16% year-over-year net sales growth for Qelbree and GOCOVRI, respectively. He also emphasized the successful launch of ONAPGO in April 2025 and the completion of the Sage Therapeutics acquisition on July 31, 2025. The strategic focus moving forward includes integrating Sage, accelerating growth through innovative CNS products, and maintaining momentum in neuropsychiatric and neurology markets.

Guidance
Supernus has updated its full-year 2025 revenue guidance, raising expectations to a range of $670 million to $700 million. This update incorporates the expected contribution from the Sage Therapeutics acquisition, which is anticipated to support mid- to long-term revenue and cash flow growth. The company also expects to initiate a Phase 2b trial for SPN-820 by year-end and finalize a lead indication for SPN-443 by December 2025.

Additional News
On August 5, 2025, Supernus announced the successful launch of Echo, its first subcutaneous apomorphine infusion device for Parkinson’s disease, marking a significant product innovation. Additionally, the company finalized the acquisition of Sage Therapeutics, which is expected to accelerate mid- to long-term revenue growth and diversify the revenue base. Supernus also revealed that Kelvi, a key growth driver, saw a 23% increase in prescriptions and a 31% rise in net sales. Goari prescriptions rose 14%, with a 16% increase in net sales attributed to improved Medicare redesign and patient retention. The company’s strong balance sheet, with $523 million in cash equivalents and no debt, further supports its strategic growth initiatives.